Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 6/20 | 0.45 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.45 |
| ▸ | F10 | P00742 | 1/20 | 0.42 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.41 |
| ▸ | ALOX5 | P09917 | 3/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.40 |
| ▸ | EGFR | P00533 | 1/20 | 0.40 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.40 |
| ▸ | ERBB4 | Q15303 | 1/20 | 0.40 |
| ▸ | AKT1 | P31749 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.39 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.39 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16495342 | 0.90 | CAPN1 (0.47) | ACHECAPN1SMYD3ALOX5EPHX2 | |
| SCHEMBL16494798 | 0.82 | CAPN1 (0.40) | CAPN1ALOX5EPHX2AKT1ALDH1A1 | |
| SCHEMBL8617331 | 0.75 | ACHE (0.46) | ACHE | |
| SCHEMBL15701646 | 0.74 | ADRB2 (0.47) | ACHECAPN1ALOX5EPHX2ALDH1A1 | |
| SCHEMBL700477 | 0.72 | ACHE (0.52) | ACHECAPN1ALOX5ALDH1A1 | |
| SCHEMBL16495161 | 0.71 | ACHE (0.50) | ACHE | |
| SCHEMBL8615723 | 0.70 | ACHE (0.59) | ACHE | |
| SCHEMBL14149903 | 0.70 | ALOX5 (0.48) | ACHEALOX5EPHX2ALDH1A1ADRB2 | |
| SCHEMBL16494819 | 0.70 | ACHE (0.54) | ACHEALDH1A1ADRB2ADRB1ADRB3 | |
| SCHEMBL6840328 | 0.70 | ACHE (0.54) | ACHECAPN1ALOX5EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110294850-A1 | INDOLINE DERIVATIVES | TOKYO INSTITUTE OF TECHNOLOGY (JP) | 2011-12-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110294850-A1 | INDOLINE DERIVATIVES | BCHE, ACHE, INMT | ACHE 2/4885CAPN1 1386/4885F10 1709/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.